The Centers for Medicare & Medicaid Services provided a reiteration of the agency’s national coverage decision regarding oncologic FDG PET this summer and clarified specifically the –KX modifier that needs to be used when clinicians code for the fourth scan and beyond.

Nematode worms are providing a very, very small window on the neural connections that we humans share. A feature in New Scientist follows the circuitous path of our knowledge about consciousness and the neural networks of the brain.

The American College of Radiology (ACR) issued a statement this week calling on the Centers for Medicare & Medicaid Services (CMS) and private insurers to cover beneficiaries for breast tomosynthesis.

A feature in The New Yorker explores how Daniela Schiller, PhD, from the Mount Sinai School of Medicine’s Brain Imaging Core in New York City, has approached a kind of memory erasure for people who have suffered greatly from post-traumatic stress disorder (PTSD) with the aid of cutting-edge neuroimaging.

The Christie NHS Foundation Trust in Manchester, U.K., is the newest institution to join an assembly of organizations with the objective of researching an integrated and real-time MR-guided radiotherapy system for more accurate treatment delivery, according to today’s announcement from Elekta and Philips Healthcare.

A preliminary imaging study with Zn-63 zinc citrate confirmed a protocol for preparation and showed encouraging preclinical biodistribution. This technique holds promise for a wide variety of diseases involving zinc disorder, including a range of cancers and metabolic disorders, according to a study published July 21 in the Journal of Nuclear Medicine.

The vast majority of women experience only mild discomfort during image-guided breast biopsy, but some, namely younger women and those anticipating stonger pain to begin with, are more likely to experience greater levels of pain during the procedure, according to a study published in the July issue of the Journal of the American College of Radiology.

The FDA announced July 14 that a shortage of Technetium Tc99m Exametazime Injection, also known as the Ceretec Kit (GE Healthcare, Medi-Physics), is in effect and expected to continue until the first week of August.